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Traditional approaches to pathophysiology are advancing but still have many limitations
that arise from real biologic systems and their associated physiological phenomena
being too complicated. Microﬂuidics is a novel technology in the ﬁeld of engineering,
which provides new options that may overcome these hurdles. Microﬂuidics handles
small volumes of ﬂuids and may apply to various applications such as DNA analysis
chips, other lab-on-a-chip analyses, micropropulsion, and microthermal technologies.
Among them, organ-on-a-chip applications allow the fabrication of minimal functional
units of a single organ or multiple organs. Relevant to the ﬁeld of nephrology, renal
tubular cells have been integrated with microﬂuidic devices for making kidneys-on-a-
chip. Although still early in development, kidneys-on-a-chip are showing potential to
provide a better understanding of the kidney to replace some traditional animal and
human studies, particularly as more cell types are incorporated toward the development
of a complete glomeruli-on-a-chip.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Technologic advances change our lifestyle in many ways.
New electronic devices become ever smaller but with
ever increasing functions, so they can replace large space-
occupying equipment. A few decades ago, microﬂuidics was
developed using advances in the semiconductor industry and
the subsequent expansion of microelectomechanical system
ﬁeld [1]. The technology can manipulate at the microscale and
control ﬂuid ﬂow precisely. Microﬂuidics has provided new
capabilities to researchers in biology and medical science.
Since early 2000, published articles and patents on micro-
ﬂuidics have increased dramatically in the ﬁeld of engineering.
Importantly, although still a smaller overall fraction, articles on15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
Medicine, Seoul National
3 Beon-gil, Bundang-gu,the use of microﬂuidics in the medical ﬁeld are growing most
rapidly at an exponential rate in recent years [2].
Microﬂuidics is characterized by the engineered manipula-
tion of ﬂuids at the submillimeter scale [2]. The microscale
devices in microﬂuidics are commonly referred to as miniatur-
ized total analysis systems or lab-on-a-chip technologies [2]. In
the 1990s to 2000s, microﬂuidics focused on the miniaturiza-
tion of previously macroscale assays. Within several years,
various new technologies showed better performances than
the traditional methods. For example, there are paper-based
analytical devices for diagnostics [3], immunoassays assisted
by surface tension [4], and organ-on-a-chip technologies [2,5]
(Fig. 1). We will further focus on organs-on-chips.Organ-on-a-chip
Organ-on-a-chip is a microﬂuidic cell culture device that is
a more physiologically relevant in vitro model than cells
cultured in dishes. Important features include continuouslyhrology. Published by Elsevier. This is an open access article under the
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Figure. 2. Concepts of organs-on-a-chip. PDMS, polydimethylsiloxane.
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simulate tissue- and organ-level physiology [5] (Fig. 2). So
far, several individual organ-on-chips have been developed,
including gut-on-a-chip [6], lung-on-a-chip [7], blood vessel-
on-a-chip [8], cancer-on-a-chip [9], bone marrow-on-a-chip
[10], and kidney-on-a-chip [11]. In addition, multiple organs-
on-a-chip has been tried, such as liver-tumor-bone marrow-
on-a-chip [12] or liver-skin-intestine-kidney-on-a-chip [13].
As shown in Fig. 3, the whole experimental process using
organ-on-a-chip technology consists of several steps. Photo-
lithography, a fabricating technique that can make channels
in a microscale, comes from semiconductor technology. It
requires labor-intensive work, clean environments, and
sophisticated training. An organ-speciﬁc microenvironment is
a basic platform in the design of these devices. Brieﬂy,
researchers design the optimal condition with the proper size,
numbers, and compartments of the channels. According to
these designs, ﬁne molds are cultivated and the ﬁnal devices
can be made out of transparent and soft polydimethylsiloxane
(PDMS) [5]. Sometimes, simple ways to make replicas can beused such as xerographic printing or three-dimensional (3D)
printing of molds.
Cell sourcing is an important issue in the organs-on-a-chip
ﬁeld. Usually, a single cell type may be enough to mimic
minimal organ function. For example, a kidney-on-a-chip for
the evaluation of direct cellular toxicity may be not enough
when constructed with renal tubular cells alone [11,14]. To
mimic more physiologic conditions or evaluate cell-to-cell
interaction, two cell types should be used like lung-on-a-chip
[7], which has cultured endothelial cells on the bottom channels
and alveolar cells on the top channels. This lung-on-a-chip also
introduced human neutrophils with culture media to the bottom
channels to observe the movement of inﬂammatory cells. Some-
times, cells in a tissue construct itself may be introduced into the
devices, such as skin tissue or intestine constructs [13]. Humans-
on-a-chip has multiple compartments to allow evaluation of the
interaction among interesting organs [13].
Why is organ-on-a-chip a hot topic?
When new drugs are developed, drugs should be tested in
three different stages: preclinical, clinical, and postapproval
stages. Preclinical studies include two kinds of experiments:
cell culture and animal studies. Cell culture methods are just
culturing living cells on a dish; there is no ﬂow of blood, and
the conditions are different from cells in a real organ. In
addition, the data from animal studies are not always pre-
dictive of human responses. They have fundamental limita-
tions such as different physiology and different cellular
functions. Kidney toxicity is one major cause of drug attrition
and failure. Only 2% of drug development failures are screened
in the preclinical stage, and serious adverse effects in 420% of
new medicines are discovered only after the clinical stages
[15]. The reason why preclinical studies cannot better predict
kidney toxicity is due to the limitations of current preclinical
cell culture and animal models.
We need real human organ–like devices that are superior to
animal models. Organ-on-a-chip may be a good solution,
which has minimal functional units that use primary human
cells, rather than animal cells, like a real human organ. The
ideal methods will not only use human cells but also mimic 3D
architecture and ﬂow conditions within real human organs.
Microﬂuidic devices seeded with human cells and perfused
with cell culture media in a physiologically relevant manner
have already been developed to provide a minimal functional
unit to mimic real organs. The small size allows easy ﬂow
control and requires few cells and only small volumes of
samples and reagents. Parallel experiments with large num-
bers of samples at the same time can also be realized. An
additional advantage of the devices is optical transparency
that allows visualization, at the cellular level, of the whole
drug response process, something that is difﬁcult to do in
actual living organs.
What are the pros and cons of organs-on-chips?
Raw materials used in these systems are inexpensive, but
specialized microengineering capabilities are needed and
some, such as cleanrooms or pumps, can be expensive. Other
challenges, such as bubbles, arise because of the small size.
Before or during the perfusion of ﬂuid, bubbles can form easily
in the channels of devices but are difﬁcult to remove. Cells in
the device are very susceptible to detachment and injury from
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face–mediated injury itself can be physiologically relevant
such as mimic lung injury [16]. In most cases, researchers
should carefully avoid bubbles or dust. For attachment of
the cells on the membranes, extracellular matrix coating is
necessary. As culturing time increases, the matrix becomes
degraded gradually, which can affect cell viability. It is also
challenging to achieve consistent cell seeding and prevent con-
tamination of microbes as many experiments require prolonged
cultures of several weeks. Organ-on-a-chip systems are still not
suitable for certain areas such as chronic diseases modeling,
adaptive immune responses, or complex system-level behaviors
of the endocrine, skeletal, or nervous systems [5]. To date, about
4 weeks may be the longest perfused models of organs-on-a-chip
[13]. Culturing suspending cells in organ-on-a-chip is still challen-
ging, although introduction of various types of attaching cells in a
chip is relatively easy [13].
In contrast, smaller experimental samples and scaling up to
larger numbers of samples can be advantageous. Through ﬂuid
ﬂow control, researchers may enhance differentiation, func-
tion, and viability or regulate microenvironmental signals.
Prediction of pharmacokinetic and pharmacodynamic proper-
ties of drugs may beneﬁt from the ability to adjust renal
clearance rates and to incorporate metabolism of an inter-
connected liver compartment. Depending on the design of the
synthetic culture system, many different parameters can be
controlled, such as types and positions of cells; orientation of
tissue–tissue interfaces; transcellular chemical, molecular, and
oxygen gradients; ﬂow levels and patterns; and mechanical
forcing regimens. A 3D cell culture can be more accurate
models of in vivo cells than 2D cell culture, but 3D culture
methods have been evaluated under the static condition
instead of dynamic conditions so far. Some combined models
between organ-on-a-chip and 3D cell culture could be an
optimal condition for mimicking in vivo microenvironments.Kidney-on-a-chip
The initial design of a published kidney-on-a-chip has two
compartments [11,14]. A top channel mimics the urinary lumen
and has ﬂuid ﬂow, whereas the bottom chamber mimics inter-
stitial space and is ﬁlled with media. Kidney cells are under much
lower shear stress than the endothelial or lung cells. This device
used rat distal tubular cells or MDCK cells, and its shear stress was
1 dyn/cm2 [11]. A second report showed the same design, but
human proximal tubular cells were used. In this model, the
authors tried to reproduce cisplatin nephrotoxicity. Proximal
tubular cells have much lower shear stress 0.2 dyn/cm2 [14].The foot processes of podocyte, a glomerular visceral epithelial
cell, form a size- and charge-selective barrier to plasma protein,
and derangement of the barrier causes podocyte injury and
proteinuria [17]. Some scientists have tried podocyte-on-a-chip,
but it is still challenging. It may be because podocyte is exposed
under a very low shear stress in vivo and requires a sophisticated
culturing condition [18].
Kidney-on-a-chip has various potential applications (Fig. 4).
Cisplatin nephrotoxicity was evaluated in the kidney-on-a-chip
using human proximal tubular cells [14]. Cisplatin was introduced
into the bottom space, and cisplatin-induced cellular damage was
monitored to the cells for 24 hours. During the following 72
hours, shear stress was helpful for facilitating recovery of the
injured cells and associated biomarkers. Shear stress in the
devices can facilitate translocation of aquaporin-2 and relocation
of actin cytoskeleton in the kidney-on-a-chip using primary
cultured inner medullary collecting duct cells of rat kidneys
[19], which is a good example of a physiological experiment
using kidney-on-a-chip. Moreover, renal tubular epithelial cells
are continuously exposed to the changes of extracellular micro-
environment, e.g., transepithelial osmotic gradient, and changes
of luminal or interstitial pH. The effects of these physiological
factors on the functions of renal tubular cells could also be
investigated by exploiting microﬂuidics [20,21]. If the offending
Kidney Res Clin Pract 34 (2015) 165–169168antigens or mechanisms of the diseases are well identiﬁed,
disease modeling can be easily fabricated in the kidney-on-a-
chip. Kidney injury models using nephrotoxic drugs may be
simple candidates for the application. Kidney-on-a-chip is only
one compartment of an eventual multiorgans-on-a-chip system
[13]. To research drug metabolism, renal excretion or metabolism
should not be omitted. However, some multiorgans-on-a-chip
systems have been using kidney tubular cells not for evaluating
renal excretion, but for measuring kidney injury. Animal renal
clearance is usually higher than human renal clearance. Using
pharmacokinetic data from animal models runs the risk of
underestimating human nephrotoxicity. Applications of human
kidney-on-a-chip may ﬁll such gaps through control of drug
concentrations and ﬂow rates that mimic human drug clearance
or metabolism.Directions for future research
PDMS can absorb small organic compounds. Lipid soluble
compounds, such as hydrophobic drugs, are incompatible with
PDMS devices because of absorption into PDMS. The same
extracellular matrix coated on PDMS can have different effects
when coated on different surfaces such as glass or polystyrene
or in the body in a cell type–dependent manner, requiring
much trial and error. There is potential need for a universal
blood substitute to perfuse multiple organ compartments.
Some studies used a mixture of various cell culture media.
Other studies used different culture media for each compart-
ment. Another issue is scaling. Isometric shrinkage of organs
creates an unbalanced system between organs because of
functions that depend on organ volume versus organ area.
There are multiple ways to scale down each organ, and what is
most appropriate is still controversial [22,23]. Automated
control systems can be helpful and may allow nonspecialists
or academic researchers to replace 2D or 3D culture systems.
Some companies have already launched commercial use of
organs-on-a-chip. Pharmaceutical and biotechnology indus-
tries have a signiﬁcant need for validation and prioritization of
lead drug candidates. In addition, clinical trials may be able to
adopt new biomarkers of drug efﬁcacy, toxicity, or disease
response developed using these devices in the near future.
Microﬂuidics is still a young and developing ﬁeld. However,
there are many opportunities for biologists and medical scien-
tists to collaborate with engineers. For example, 3D organoid
cultures, dynamic cultures, and disease modeling are areas
where collaborations have led to better understanding of
pathophysiology and mechanisms. Multiorgan-on-a-chip or
human-on-a-chip is a young but exciting area. In the nephrology
ﬁeld, glomeruli-on-a-chip, kidney organoid, and nephron-on-a-
chip are still challenging. Organs in the human body are vital but
difﬁcult to manipulate and image at the cellular level, making
evaluation of their functions and responses difﬁcult. In contrast,
the use of organs-on-a-chip is relatively cheap, readily imaged,
and easily accessible for measurement of functions and will
provide a vital window into human physiology in ways not
currently possible.Conﬂicts of interest
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